Trial Profile
A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Blood mononuclear cell therapy (Primary) ; Blood mononuclear cell therapy (Primary)
- Indications Chronic limb-threatening ischemia; Diabetic complications; Leg ulcer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beike Biotechnology
- 07 May 2014 New trial record